SOURCE: Medistem Inc.

Medistem Inc.

July 15, 2013 09:00 ET

Medistem Files Registration Statement With Securities and Exchange Commission

Clinical-Stage Stem Cell Company to Re-Enter Public Capital Markets

SAN DIEGO, CA--(Marketwired - Jul 15, 2013) - Medistem, Inc. (PINKSHEETS: MEDS), announced today that it has filed a Form 10 registration statement with the Securities and Exchange Commission. The filing is part of the Company's strategy to become fully reporting and access the public capital markets. It is expected that the Form 10 will become effective 60 days from the filing date, allowing liquidity for existing shareholders.

In 2009, the Company voluntarily elected to stop reporting under the 1934 Securities and Exchange Act to focus its resources on advancing its lead product, ERC-124, a universal donor stem cell. The Company successfully obtained FDA clearance to initiate clinical trials for its product in patients with critical limb ischemia (CLI). In addition, the Company has treated 18 congestive heart failure (CHF) patients in an ongoing double-blind placebo controlled trial.

On October 2012, the Company strengthened its management team with the addition of biopharmaceutical veteran Alan J. Lewis, Ph.D. as Chief Executive Officer. Dr. Lewis has previously served as CEO and Chairman of Ambit BioSciences, CEO of the Juvenile Diabetes Research Foundation, President, CEO and Director of Novocell, Inc., and CEO and Director of Signal Pharmaceuticals. Dr. Lewis also serves as a Director of BioMarin Pharmaceutical Inc (NASDAQ: BMRN).

Additionally, during the first quarter of this year, John Chiplin and Herm Rosenman, were appointed as independent board members. Dr. Chiplin is currently CEO of Polynoma, Inc., and was founding CEO of Arana Therapeutics prior to its acquisition by Cephalon for $329 million. In addition to serving on a number of public and private boards, Mr. Rosenman was Senior Vice President and Chief Financial Officer of Gen-Probe, Inc., until its acquisition by Hologic, Inc., in August 2012 for $3.7 billion.

"We believe that having strengthened our intellectual property portfolio, obtaining clinical data from 18 patients treated in our CHF trial, and attaining FDA clearance to begin a CLI trial, has increased our value to the investment community," said Dr. Lewis. "The filing of the Form 10 represents the next step in our growth, which will position us to attract institutional investment and Wall Street support."

The Company's Form 10 and accompanying exhibits filed with the Securities and Exchange Commission can be found at:

About Medistem, Inc.

Medistem, Inc., is developing ERC-124, a universal stem cell product derived from the endometrium. ERC-124 possesses specialized abilities to stimulate new blood vessel formation and can differentiate into lung, liver, heart, brain, bone, cartilage, fat and pancreatic tissue. These unique properties have applications for treatment of critical limb ischemia (CLI), congestive heart failure (CHF), neurodegenerative diseases, liver failure, kidney failure, and diabetes. ERC-124 has been cleared by the FDA to begin a CLI clinical trial in the United States. In January 2012, the Company announced the initiation of its RECOVER-ERC (Non-Revascularizable IschEmic Cardiomyopathy treated with Retrograde COronary Sinus Venous DElivery of Cell TheRapy) a double blind, placebo controlled, clinical trial. This trial is being conducted at the Bakulev Scientific Center for Cardiovascular Surgery, Moscow, Russia. The trial is a 60 patient double blind placebo controlled study evaluating safety and efficacy of ERC-124 in end stage CHF patients.

Certain statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Medistem, Inc. These can be identified by the use of forwardlooking words, such as "believes", "expects", "may", "intends", "anticipates", "plans", "estimates", or any other analogous or similar expressions intended to identify forwardlooking statements. These forwardlooking statements and estimates as to future performance, estimates, and other statements contained herein regarding matters that are not historical facts, are only predictions and actual events or results may differ materially. We cannot assure or guarantee that any future results described in this presentation will be achieved, and actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Contact Information